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Microbiologic and epidemiologic investiga-
tions have begun to elucidate the major
sources of fluoroquinolone (FQ)-resistant
Campylobacter infections in the United States.
Major findings include the following: a)a n
increasing proportion of isolates collected in
the United States from human Campylobacter
infections are resistant to FQs [Allos 2001;
Centers for Disease Control and Prevention
(CDC) 2003; Nachamkin et al. 2002];
b) studies of human stool samples taken
before FQ therapy indicate that most of the
infections were resistant before treatment
(Gaunt and Piddock 1996; Smith et al. 1999);
c) epidemiologic studies indicate that fresh
poultry products are the major sources of
Campylobacter infections in humans (Harris
et al. 1986; Neimann et al. 2003); d) FQ-
resistant Campylobacter populations develop
quickly in Campylobacter-infected chickens
that are treated with FQs (McDermott et al.
2002); and e) in the United States, consumer-
ready fresh poultry products are commonly
contaminated with FQ-resistant strains of
Campylobacter (Ge et al. 2003). It has been
inferred from these ﬁndings that a large num-
ber of FQ-resistant Campylobacter infections in
humans are the result of FQ use in the poultry
house. Some of the strongest evidence to sup-
port this connection comes from a recent
study of human campylobacteriosis in
Australia, where despite regular clinical use of
FQs and normal rates of Campylobacter infec-
tion, there are no conﬁrmed cases of domesti-
cally acquired FQ-resistant campylobacteriosis
(Unicomb et al. 2003). The authors concluded
that this dramatic phenomenon is likely related
to Australia’s prohibition of FQ use in poultry
production.
FQs, Sara Flox WSP (saraﬂoxacin water-
soluble powder; Abbott Laboratories, North
Chicago, IL) and Baytril (enroﬂoxacin; Bayer
Corporation, Shawnee Mission, KS), have
been approved for use in the United States to
control Escherichia coli infections in broiler
chickens since 1995 and 1996, respectively
[Food and Drug Administration (FDA) 1995,
1996]. In October 2000, the FDA’s Center
for Veterinary Medicine announced that it
intended to withdraw approval for FQs in
poultry production because new evidence had
shown that it may not be safe for human
health (FDA 2000a). In March 2004, the
FDA’s regulation was upheld in court, but
Bayer has appealed this decision. Although
this battle continues, Baytril continues to be
marketed for use as a drinking water additive
for ﬂock-wide application in broiler produc-
tion. The exact number of birds treated with
Baytril annually is not publicly available, but
Bayer estimated that < 1% of the American
poultry flock was treated with the drug in
2001 (Bayer Healthcare 2004). Given the
enormous scale of the American poultry ﬂock
(~ 8.4 billion in 2001), this estimate indicates
that up to 84 million birds may be treated
with Baytril annually [U.S. Department of
Agriculture (USDA) 2002]. In February
2002, in response to public concerns regard-
ing FQ use in poultry production, two major
U.S. producers, Tyson and Perdue, separately
announced that they would stop using FQs in
drinking water to treat poultry ﬂocks (Perdue
Farms 2002; Tyson Foods 2002).
A recent survey of Campylobacter from raw
poultry products indicated that 35% of iso-
lates were resistant to ciproﬂoxacin (CIP) (Ge
et al. 2003). Ge et al. (2003) used standard
FDA methodologies in which Campylobacter
colonies were isolated on Campylobacter
media and a small sample of colonies (typi-
cally no more than three) was tested for sus-
ceptibility to FQs. Because poultry products
are often contaminated with mixed popula-
tions of Campylobacter strains with differing
FQ susceptibilities, this assay has question-
able sensitivity, and the 35% ﬁgure reported
previously is considered to underestimate the
actual prevalence of FQ-resistant strains
(FDA 2000b).
In the present study, we performed a sur-
vey of fresh poultry products from two of the
countries largest conventional producers,
Tyson Foods and Perdue Farms, and two
“antibiotic-free” producers, Bell & Evans and
Eberly. Campylobacter strains were isolated
using standard FDA methodology and also by
a modiﬁed method that included FQ-supple-
mented agar medium to identify resistant
strains among a mix of susceptible and resis-
tant strains. We analyzed our results comparing
FQ-resistant Campylobacter carriage among the
two “antibiotic-free” and the two conventional
brands and tested the increased sensitivity
gained by using FQ-supplemented agar.
Materials and Methods
Sampling and enrichment. Fresh chicken
products from two antibiotic-free producers,
Bell & Evans (Fredericksburg, PA; A) and
Eberly Poultry (Stevens, PA; B), and two con-
ventional producers, Perdue Farms (Salisbury,
MD; C), and Tyson Foods (Springdale, AR;
D), were purchased seven to eight times from
grocery stores in the Baltimore, Maryland,
area over the course of 10 weeks (from
25 February to 13 May 2003; Table 1). All
samples were purchased in packaging applied
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flock-wide treatment. One year later, we began a survey of Campylobacter isolates on chicken
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detection of FQ-resistant Campylobacter, we compared rates of FQ-resistant Campylobacter
among these products. Four major ﬁndings were drawn from this study: a) antibiotic-free brands
were not more likely to be contaminated with Campylobacter; b) a high percentage of products
from the two conventional brands were contaminated with FQ-resistant Campylobacter (43 and
96%); c) these conventional brands had signiﬁcantly higher odds of carrying resistant strains com-
pared with antibiotic-free products; and d) supplementing media with FQs increased the sensitivity
of detecting FQ-resistant strains among mixed populations of Campylobacter, thus reducing a bias
toward underestimating the prevalence of FQ-resistant Campylobacter on samples. These results
suggest that FQ resistance may persist in the commercial poultry environment in the absence of
FQ-selective pressure and that these strains contaminate a larger proportion of foods than reported
previously. Key words: bacterial, Campylobacter, chickens, drug resistance, drugs, ﬂuoroquinolones,
food microbiology, methods, poultry, veterinary. Environ Health Perspect 113:557–560 (2005).
doi:10.1289/ehp.7647 available via http://dx.doi.org/ [Online 2 February 2005]at the processing plant, and all products were
“bone-in” and “skin-on” (i.e., not skinless
boneless products). On most occasions, three
separate packages from the four producers were
purchased each time; all three samples were
purchased from the same grocer on a given
date and were typically from the same produc-
tion lot. Packages were refrigerated at 4°C until
they were sampled (within 48 hr of purchase). 
A single piece of chicken was sampled
from each package. The package was wiped
with 70% ethanol and cut open with a new
disposable razor blade, and the plastic cover
was removed and photocopied for record
keeping. Sterile forceps were used to transfer a
single piece of chicken to a stomacher bag
containing 200 mL sterile Bolton broth sup-
plemented with laked horse blood (Oxoid,
Ogdensburg, NY; Quad Five, Ryegate, MT).
Samples were then shaken by hand for 2 min.
Chicken was removed using forceps, and the
bag was sealed 1–2 cm above the top of the
broth. Enrichments were incubated at 42°C
for 22–26 hr.
Isolation. Ten microliters of the enrich-
ment [~ 106 colony forming units (CFU)]
was streaked onto Abeyta-Hunt agar (Hunt
et al. 2000) with and without 4 µg/mL CIP
(U.S. Biological, Swampscott, MA) and incu-
bated for 22–26 hr at 42°C. A single typical
Campylobacter colony from each of the two
media was streaked for isolated colonies on
Campylobacter blood agar (Fisher Scientific,
Hampton, NH). A single puriﬁed colony was
then streaked for confluent growth on
Campylobacter blood agar and incubated for
22–26 hr. A 10-µL loopful of cellular material
was transferred to Campylobacter freezing
medium (Hunt et al. 2000).
DNA isolation. DNA was isolated from a
second loopful of material using the DNeasy
tissue kit (Qiagen, Valencia, CA).
Species conﬁrmation. Presumptive Campy-
lobacter isolates were confirmed and the
species identified using a polymerase chain
reaction (PCR) ampliﬁcation/restriction digest
protocol described previously (Engvall et al.
2002). Briefly, THERM1 and THERM4
PCR primers were used to amplify a region of
DNA speciﬁc to thermophilic members of the
genus Campylobacter. This PCR product was
then digested in two separate reactions using
the restriction endonucleases AluI and
Tsp509I. The species-speciﬁc restriction pat-
terns produced from this digestion enabled us
to identify the species of each isolate.
Susceptibility. Susceptibility to CIP was
determined using standard Clinical and
Laboratory Standards Institute and Campylo-
bacter-specific methods described previously
(McDermott and Walker 2003). Briefly,
Campylobacter isolates were grown overnight
on Campylobacter blood agar (Fisher) under
microaerophilic conditions. Colonies were
suspended to approximately 0.5 McFarland
standard in Mueller-Hinton broth and inocu-
lated onto Mueller-Hinton agar supple-
mented with 5% sheep blood and CIP (U.S.
Biological) ranging from 0.12 to 32 µg/mL.
Plates were grown 22–26 hr at 42°C under
microaerophilic conditions. The reference
strain used was Campylobacter jejuni ATCC
33560 (American Type Culture Collection,
Rockville, MD). Strains were designated resis-
tant if their minimum inhibitory concentra-
tion was > 4 µg/mL.
gyrA QRDR sequence analysis. The
nucleotide sequence of the quinolone-
resistance–determining region (QRDR) of
gyrA was sequenced from isolates using the fol-
lowing primer pair designed from the
Campylobacter whole-genome DNA sequence
(Parkhill et al. 2000): Cj gyrA QRDR F,
GCC TGA CGC AAG AGA TGG TTT A;
and Cj gyrA QRDR R, TAT GAG GCG
GGA TGT TTG TCG. Multilocus sequence
typing analysis was used to further characterize
some isolates as described previously (Dingle
et al. 2001).
Statistical analysis. We performed statisti-
cal analyses using Stata 8.0 (StataCorp,
College Station, TX). We used Fisher’s exact
tests to compare the rates of undifferentiated
Campylobacter (susceptible and resistant) car-
riage and FQ-resistant Campylobacter carriage
across the brands. Odds ratios (ORs) of undif-
ferentiated and FQ-resistant Campylobacter
carriage with corresponding exact 95% conﬁ-
dence intervals (CIs) were computed for all
pair-wise comparisons across the brands.
Results
Overall, Campylobacter was detected on 84%
of the chicken tested, and FQ-resistant strains
were detected on 17% using unsupplemented
media and on 40% using agar supplemented
with 4 µg/mL CIP (Table 2). When the two
methods resulted in the isolation of strain pairs
of different FQ susceptibilities, analysis of the
gyrA, aspA, glnA, gltA, glyA, pgm, and tkt genes
from the two isolates revealed that most of
these pairs (19 of 21) also differed at two or
more nucleotides (data not shown). That is to
say, 19 of the 21 resistant isolates were shown
to be genetically unique from their susceptible
counterparts and would have been missed
using standard isolation techniques (i.e.,
unsupplemented media). In contrast, only two
strains were found to be within a single poly-
morphism (among the seven genes examined)
of their susceptible counterparts. Therefore, as
potential sporadic mutants isolated by chance,
these two strains represent the maximum
potential loss in assay speciﬁcity.
DNA sequence analysis of the gyrA gene
revealed that all resistant strains isolated in
this survey had a Thr86→Ile substitution, as
reported previously by Wang et al. (1993).
Using Fisher’s exact test, we were able to
reject the null hypothesis that the rates of undif-
ferentiated Campylobacter (susceptible and resis-
tant) carriage are the same for all the brands
(p < 0.001). Table 3 displays the pair-wise odds
ratios of undifferentiated Campylobacter car-
riage and exact 95% CIs among the brands.
We found that brand A (antibiotic-free) had
significantly lower carriage rates compared
with the other producers.
Given the robustness of the selective assay
data, all comparative statistical analyses were
performed using the data resulting from the
CIP-supplemented media. We found statisti-
cally signiﬁcant differences in the rates of FQ-
resistant Campylobacter carriage across the
brands (Fisher’s exact test, p < 0.001). The pair-
wise analysis of FQ-resistant Campylobacter
carriage among the brands is presented in
Table 4. Brand D (conventional) had a 96%
carriage rate for FQ-resistant Campylobacter
and signiﬁcantly higher odds of carrying these
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Table 1. Summary of dates and samples tested.
Purchase dates
Brand 25 Feb 4 Mar 11 Mar 25 Mar 1 Apr 22 Apr 29 Apr 13 May
A TTT TTTTT
Ba  NWW W WDD L
C TTT TT NTT
D TTT TTTTT
Abbreviations: D, drumstick; L, leg; N, no sample; T, thigh; W, whole chicken.
aThighs from antibiotic-free brand B were not available in the Baltimore area at the time of the sampling.
Table 2. Percentage (n) of samples testing positive for Campylobacter and FQ-resistant Campylobacter
carriage, by brand and medium.
Nonselective medium, Selective medium,
Brand Undifferentiated CIP-resistant CIP-resistant
(no. of samples) Campylobacter Campylobacter Campylobacter
Antibiotic-free A (24) 54 (13) 13 (3) 13 (3)
B (21) 95 (20) 0 (0) 5 (1)
Conventional C (21) 90 (19) 19 (4) 43 (9)
D (24) 100 (24) 33 (8) 96 (23)
Total All (90) 84 (76) 17 (15) 40 (36)strains than did each of the other brands. The
biggest difference in odds of FQ-resistant
Campylobacter carriage was observed when
comparing brand D with brand B (antibiotic-
free). Speciﬁcally, we estimated that the odds
of FQ-resistant carriage in brand D was
460 times greater than the odds of FQ-resistant
carriage in brand B (95% CI, 21.7–19766.8).
There was no significant difference between
the two antibiotic-free brands when compared
with one another.
Discussion
Limitations of the study. The present study
has three primary limitations. First, the study
was limited in the number of stores sampled
and its geographical region. However, this
was not likely to reduce the generalizability of
the results because we used products that are
widely distributed in the United States.
Moreover, we carefully selected packages that
were sealed at the processing facility by the
producer so that store-related factors would
not affect the prevalence of FQ-resistant
Campylobacter. Second, the sampling period
(25 February to 13 May 2003) was relatively
short. Because of this, we could not detect any
potential seasonal variation in carriage rates.
Finally, we were not able to test the same cut
(e.g., thigh) each time from each producer,
which would have been ideal. This was
because thighs were not available for brand B
during the testing period. However, given that
we measured the presence or absence of
Campylobacter on chicken products, rather
than the quantity of Campylobacter on a given
sample, this variation likely did not affect the
overall outcome of the study.
Lingering FQ-resistant Campylobacter.
On 18 February 2002, Tyson announced that
it planned to discontinue FQ use and esti-
mated use in previous years to be approxi-
mately 0.2% (Tyson Foods 2002). Shortly
thereafter, on 25 February 2002, Perdue
announced that they would immediately stop
using FQ and also claimed FQs had not been
used within the previous year (Perdue Farms
2002). However, 1 year later, we found signif-
icant proportions of products from both of
these companies that carried FQ-resistant
strains of Campylobacter. Accepting the verac-
ity of these announcements, our data suggest
that past FQ use may have persistent effects
on Campylobacter populations in poultry
houses. This is consistent with reports from
Denmark indicating that vancomycin-resistant
enterococci could be isolated from broiler
ﬂocks 5 years after avoparcin was banned for
use in broilers in that country (Heuer et al.
2002). These studies challenge the notion that
resistant populations will quickly revert to a
susceptible state once antimicrobial pressure is
removed. Indeed, models indicate that
microbes may be more likely to develop com-
pensatory mutations that ease the metabolic
costs of resistance determinants rather than
simply revert back to a susceptible phenotype
(Levin et al. 2000).
Inadequate hygiene. If what we observed
is an indication of lingering resistance, it may
be important to improve cleaning and disin-
fection between ﬂocks. Bioﬁlms in water dis-
tribution systems have been identified as
potential sources of Campylobacter infection
in poultry houses (Trachoo et al. 2002).
Baytril is administered through poultry
drinking water systems; therefore, this could
be an important reservoir of FQ-resistant
Campylobacter. Studies using molecular
fingerprinting techniques have provided
mixed indications of the importance of insuf-
ficient floor sanitation to the carryover of
Campylobacter isolates, and it is clear that
some strains do persist from flock to flock
(Petersen and Wedderkopp 2001; Shreeve
et al. 2002). This problem may be magniﬁed
in the United States, where many poultry
houses are built with dirt ﬂoors and are typi-
cally cleaned only every 2–3 years (Hayes
et al. 2000). This practice may support a long-
term reservoir for FQ-resistant Campylobacter
infections of subsequent ﬂocks.
Cross-contamination. The microbes on
fresh poultry products may reflect the cecal
contents of the individual bird at harvest as
well as conditions in the processing plant.
Modern plants can process > 200,000 broilers/
day, and Campylobacter strains found on
poultry carcasses after processing can be sig-
nificantly different from those found in the
flock before slaughter (Newell et al. 2001).
Therefore, the presence of antimicrobial-
resistant Campylobacter on a particular broiler
carcass may result from contamination of the
slaughter equipment by a broiler flock
processed previously. This issue is particularly
relevant to the antibiotic-free producers
whose broiler products may become contami-
nated with antimicrobial-resistant bacteria in
abattoirs that process both antibiotic-free and
conventional flocks. Both of the antibiotic-
free producers included in this study process
their broilers in facilities that are also used for
antimicrobial-treated flocks. However, no
FQ-treated ﬂocks are said to be processed in
the brand A abattoir (Ranck S, personal com-
munication). Such a claim could not be made
for the brand B abattoir (Carson E, personal
communication).
Enhancing the sensitivity of detecting
antibiotic resistance in food isolates. The sensi-
tivity of antibiotic resistance surveys can be sig-
niﬁcantly enhanced by including a selective step
in the isolation procedure. The Campylobacter
isolation methodology recommended by the
FDA and used in the National Antibiotic
Resistance Monitoring Service (NARMS) does
not include a selective isolation step. Without
such a step, this method is likely to under-
estimate the presence of resistant strains when
they exist among a group of mixed suscepti-
bility strains. The results of the present study
indicate that the risk of underestimation
using nonselective media likely outweighs the
risk of potential false positives due to sporadic
mutation during enrichment. We observed
no difference between the numbers of resis-
tant isolates determined by the two methods
on the brand A (antibiotic-free) samples.
Furthermore, despite the fact that most
brand B (antibiotic-free) samples were posi-
tive for Campylobacter (20 of 21), only one
sample gave conﬂicting results using the two
different assays. DNA sequence analysis
revealed that the two strains isolated from this
sample were genetically distinct (i.e., differed
by more than one polymorphism).
Campylobacter strains have been shown to
develop quinolone resistance at an average
rate of 5 × 10–9 (Taylor et al. 1985; Wang
et al. 1993; Wang and Taylor 1990), with a
few strains reported to develop at rates as high
as 5 × 10–7 (Bachoual et al. 2001; Payot et al.
2002; Wang et al. 1993). Using the standard
FDA protocol, approximately 106 CFU are
transferred to a plate from enrichment
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Table 3. Pair-wise comparisons of the odds of
undifferentiated Campylobacter (susceptible and
resistant) carriage among brands.
Reference Comparison ORa
brand brand (95% CI)b p-Valuec
A B 16.9 (1.9–763.8) < 0.01
C 8.0 (1.3–85.6) 0.01
D 40.6 (4.8–∞) < 0.01
B C 0.5 (0.01–10.0) > 0.99
D 2.4 (0.0–∞) 0.47
C D 5.0 (0.61–∞) 0.21
aZero counts were replaced with 0.5 in order to estimate
ORs for comparisons with D. b95%CIs are based on exact
methods; upper bounds of the 95% CI were not estimable
for comparisons with D. cBased on Fisher’s exact test for
each pair-wise comparison.
Table 4. Pair-wise comparisons of the odds of FQ-resistant Campylobacter carriage among brands.
Reference brand Comparison brand OR (95% CI) p-Value
A B 0.4 (0.01–4.9) 0.61
C 5.3 (1.0–34.7) 0.04
D 161.0 (13.5–6924.0) < 0.01
B C 15.0 (1.6–689.3) < 0.01
D 460.0 (21.7–19766.8) < 0.01
C D 30.7 (3.3–1365.6) < 0.01
“Antibiotic-free” Conventional 25.2 (6.8–111.4) < 0.01(assuming a 10-µL calibrated loop and an
overnight Campylobacter culture grown in
Bolton broth). Therefore, on average, one
would expect to isolate a random mutant with
a frequency of approximately 1 in 200 assays.
In the present study, sequence typing analysis
was used to examine the genetic background
of strains isolated using the two different
methods. In 19 of 21 cases, the strains dif-
fered at multiple nucleotides unrelated to
resistance. The most parsimonious explana-
tion for the observed difference in strains iso-
lated by the two methods is that these poultry
samples were contaminated with mixed popu-
lations of FQ-susceptible and FQ-resistant
strains. Under such conditions, the likelihood
of isolating resistant strains using nonselective
conditions is dependent upon variables such
as relative starting concentration and dou-
bling time of individual strains in the enrich-
ment broth. Using the selective method
minimized potential masking of the effects of
such variables.
Implications for public health. Despite
high incidence rates, mortality due to
Campylobacter infections is rare in the United
States. Most healthy individuals are thought to
pass infections without the aid of antimicrobial
therapy within 7–10 days. In contrast, anti-
microbial therapy can be critical for the treat-
ment of Campylobacter infections in the elderly
and the immunocompromised (Djuretic et al.
1996; Manfredi et al. 1999; Tee and Mijch
1998). CIP is a commonly prescribed anti-
microbial for campylobacteriosis (Nachamkin
et al. 2002), and the emergence of FQ-resistant
Campylobacter strains magniﬁes the threat to
at-risk populations (Anderson et al. 2003).
Therefore, it is critical to accurately measure
the prevalence of FQ-resistant Campylobacter
in the food supply and to identify the factors
contributing to their presence.
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